Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;183(4):1891-1900.
doi: 10.1007/s00431-024-05450-5. Epub 2024 Feb 6.

Visual impairment burden in retinopathy of prematurity: trends, inequalities, and improvement gaps

Jianqi Chen #  1 , Yingting Zhu #  1 , Linling Li #  2 , Juan Lv #  2 , Zhidong Li  1 , Xuhao Chen  1 , Xiaohong Chen  1 , Shaofen Huang  1 , Rui Xie  1 , Yuan Zhang  1 , Guitong Ye  1 , Ruiyu Luo  1 , Xinyue Shen  1 , Min Fu  3 , Yehong Zhuo  4
Affiliations

Visual impairment burden in retinopathy of prematurity: trends, inequalities, and improvement gaps

Jianqi Chen et al. Eur J Pediatr. 2024 Apr.

Abstract

Retinopathy of prematurity (ROP) is an important cause of avoidable childhood visual impairment, and the increase in number and survival of premature infants may inflate its burden globally. We aimed to comprehensively assess the trends and inequalities in the burden of ROP-related visual impairment and to identify improvement gaps to facilitate appropriate actions in neonatal care systems. We obtained ROP data from the Global Burden of Disease 2019 study. We employed joinpoint regression analysis to assess the trends of the burden of ROP-related visual impairment, measured by age-standardised prevalence rates, health equity analysis methods to evaluate cross-country burden inequalities, and data envelopment and stochastic frontier analyses to identify improvement gaps based on the development status, i.e., sociodemographic index (SDI). Between 1990 and 2019, the age-standardised prevalence rates of ROP-related visual impairment significantly increased worldwide (average annual percentage change: 0.23 [95% confidence interval, 0.21-0.26] among males and 0.26 [0.25-0.27] among females), primarily in developed regions. Although significant SDI-related cross-country inequalities were identified, these reduced over time (slope index of inequality: -57.74 [-66.22 to -49.25] in 1990 to -29.68 [-38.39 to -20.97] in 2019; health concentration index: -0.11 [-0.13 to -0.09] in 1990 to -0.07 [-0.09 to -0.06] in 2019). Notably, some less-developed countries exhibited superior performance despite limited resources, whereas others with a higher SDI delivered lagging performance. Conclusion: The global burden of ROP-related visual impairment has steadily increased between 1990 and 2019, with disproportionate burden concentration among less-developed countries, requiring appropriate preventive and intervention measures. What is Known: • Retinopathy of prematurity (ROP) is an important cause of avoidable childhood visual impairment. • The prevalence of ROP is anticipated to increase due to the growing number of extremely premature infants. What is New: • The prevalence of ROP-related visual impairment has increased worldwide, primarily in developed regions, with declining but persisting cross-country inequalities. • The increasing burden of ROP-related visual impairment should be considered as part of global and national health agendas, requiring interventions with proven efficacy.

Keywords: Disease burden; Health inequalities; Improvement gaps; Retinopathy of prematurity; Trend analysis; Visual impairment.

PubMed Disclaimer

References

    1. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B; Cryotherapy For Retinopathy of Prematurity Cooperative Group (2020) Incidence and early course of retinopathy of prematurity. Ophthalmology 127:S84–S96. https://doi.org/10.1016/j.ophtha.2020.01.034 - DOI
    1. Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84:77–82. https://doi.org/10.1016/j.earlhumdev.2007.11.009 - DOI - PubMed
    1. Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, Weisberger A, Stiehl DP, Fleck B, RAINBOW investigators group, (2021) 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health 5(10):698–707. https://doi.org/10.1016/S2352-4642(21)00195-4 - DOI - PubMed
    1. Msall ME, Phelps DL, DiGaudio KM, Dobson V, Tung B, McClead RE, Quinn GE, Reynolds JD, Hardy RJ, Palmer EA (2000) Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years. Behalf of the cryotherapy for retinopathy of prematurity Cooperative Group. Pediatrics 106:998–1005. https://doi.org/10.1542/peds.106.5.998 - DOI - PubMed
    1. Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF, Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators, (2003) Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 289:1124–1129. https://doi.org/10.1001/jama.289.9.1124 - DOI - PubMed